Wełnicki, M. (2025) “Why we choose fenofibrate? Fenofibrate in long-term therapy – larger packages, greater benefits for patients with atherogenic dyslipidemia”, Medycyna Faktow (J EBM), 18(2(67), pp. 290-292. doi: 10.24292/01.MF.0225.18.